Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Letrozole or Anastrozole. A Phase II Trial Conducted by the Hellenic Group of Oncology (HELGO)
| Autor: | Vasilis Kouloulias, Dionysios Voros, Despina Mouratidou, Constantine Gennatas, Nikolaos Tsavaris, Nikiforita Poulakaki, J. Psychogios, Vasiliki Michalaki, George Katsiamis, Eleni Carvounis |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Neoplasms Hormone-Dependent Antineoplastic Agents Hormonal Anastrozole Breast Neoplasms macromolecular substances 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Exemestane Internal medicine Nitriles medicine Humans Treatment Failure Aged Neoplasm Staging Greece Aromatase Inhibitors business.industry Letrozole Cancer General Medicine Middle Aged Triazoles medicine.disease Metastatic breast cancer Androstadienes Postmenopause Clinical trial Treatment Outcome 030104 developmental biology chemistry 030220 oncology & carcinogenesis Disease Progression Female business medicine.drug Hormone |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 2038-2529 0300-8916 |
| Popis: | Aims and Background The understanding of hormonal therapies in postmenopausal women with metastatic breast cancer has advanced greatly in the past several decades. With the introduction of orally active, potent and selective third-generation aromatase inhibitors (anastrozole, letrozole and exemestane), approaches to the treatment of hormone-sensitive advanced breast cancer are undergoing reevaluation. For treatment of advanced or metastatic disease that has progressed on tamoxifen, all three agents are active. The purpose of the study was to assess the antitumor efficacy and tolerance of exemestane administered as third-line hormonal therapy to postmenopausal women with metastatic breast cancer refractory to letrozole and anastrozole. Study design Sixty postmenopausal women with stage IV hormone receptor-positive carcinoma of the breast were enrolled in the study. All patients had received two prior hormonal manipulations and had measurable or assessable disease. All adverse events were monitored. Results Objective tumor response was achieved in 12 (20%) patients (95% CI, 9.6-30.4). The overall clinical benefit was 38.3% (95% CI, 21.2-49.3), and the median duration of objective tumor response was 20 months (range, 9-26). The median time to death was 17.4 months (95% CI, 16.14-18.66). Conclusions Exemestane represents an active and well-tolerated treatment option in pretreated patients with advanced breast cancer who have received standard first- and second-line hormonal therapies. By extending the sequence of hormonal therapy, disease progression and the need for chemotherapy may be significantly delayed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|